Climb Bio, INC. (CLYM) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Dec 31, 2025
• 8-K Filing — Dec 11, 2025
• Climb Bio, Inc. Files 8-K — Oct 17, 2025 Risk: low
  Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 17, 2025, reporting other events. The company, incorporated in Delaware with its pri
• Climb Bio, Inc. Files 8-K on Officer/Director Changes — Oct 1, 2025 Risk: medium
  Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 1, 2025, reporting on events as of September 30, 2025. The filing covers the departu
• Climb Bio, Inc. Files 8-K — Sep 29, 2025 Risk: low
  Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on September 29, 2025, reporting on other events and financial statements. The company, incorpo
• Climb Bio Director Departs, Board Changes Announced — Jun 18, 2025 Risk: medium
  Climb Bio, Inc. announced on June 12, 2025, the departure of Director Dr. David S. Rickman. The company also reported on the election of new directors and chang
• Climb Bio, Inc. Files 8-K on Security Holder Vote — Jun 5, 2025 Risk: low
  Climb Bio, Inc. filed an 8-K on June 5, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The company, formerly known as
• Climb Bio Appoints New CEO, Board Shakeup — Apr 1, 2025 Risk: medium
  Climb Bio, Inc. announced on March 27, 2025, a series of executive and board changes. Dr. Jonathan M. Rothberg has been appointed as the new Chief Executive Off
• Climb Bio, Inc. Files 8-K on Material Agreements — Mar 25, 2025 Risk: low
  On March 25, 2025, Climb Bio, Inc. filed an 8-K report detailing a material definitive agreement, results of operations, and financial condition. The company, f
• Climb Bio, Inc. Files 8-K on Material Agreements — Jan 10, 2025 Risk: medium
  On January 8, 2025, Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K report detailing a material definitive agreement, results of operations, an
• Climb Bio, Inc. (fka Eliem Therapeutics) Files 8-K — Oct 15, 2024 Risk: low
  On October 15, 2024, Climb Bio, Inc. filed an 8-K report. The filing indicates that the company was formerly known as Eliem Therapeutics, Inc. and changed its n
• Climb Bio, Inc. Files 8-K with Corporate Updates — Oct 2, 2024 Risk: low
  Climb Bio, Inc. filed an 8-K on October 2, 2024, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements. The co
• Eliem Therapeutics Reports Director Changes — Aug 27, 2024 Risk: low
  Eliem Therapeutics, Inc. filed an 8-K on August 23, 2024, reporting the departure of a director and the election of a new director. The filing also details comp
• Eliem Therapeutics Names New Directors, Updates Exec Pay — Aug 26, 2024 Risk: low
  Eliem Therapeutics, Inc. announced on August 26, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elec
• Eliem Therapeutics Files 8-K on Operations — Aug 14, 2024 Risk: low
  Eliem Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Santhera Acquires Eliem Therapeutics for $10.5M — Jun 27, 2024 Risk: medium
  Eliem Therapeutics, Inc. announced on June 27, 2024, the completion of its acquisition by a subsidiary of Santhera Pharmaceuticals (Holding) AG. This transactio
• Eliem Therapeutics Files 8-K for Security Holder Votes and Other Events — Jun 26, 2024 Risk: low
  Eliem Therapeutics, Inc. filed an 8-K on June 26, 2024, to report on matters submitted to a vote of its security holders and other events. The filing does not c
• Eliem Therapeutics Appoints New CMO, Directors — Jun 12, 2024 Risk: medium
  Eliem Therapeutics, Inc. announced on June 12, 2024, the appointment of Dr. Andrew R. Haskins as Chief Medical Officer and the election of Dr. Sarah L. Hough an
• Eliem Therapeutics Announces Officer Departure, Equity Sales — Apr 11, 2024 Risk: medium
  Eliem Therapeutics, Inc. announced on April 10, 2024, the departure of Dr. Andrew Reisner from his role as Chief Medical Officer. The company also disclosed inf
• Eliem Therapeutics Relocates Principal Executive Offices — Mar 19, 2024 Risk: low
  Eliem Therapeutics, Inc. filed an 8-K on March 19, 2024, reporting an event on March 14, 2024. The filing indicates a change in the company's principal executiv

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX